Pharmacist Cardiovascular | Specialty | Stroke On-Demand 1h

Using factor Xa inhibitors to treat VTE and prevent stroke in patients with atrial fibrillation continues to increase. However, major bleeding including intracranial hemorrhage remains a significant risk, and the ideal reversal agent is still unknown. Take this course to learn about the differences in reversal, safety, and efficacy outcomes when patients were given andexanet alfa or prothrombin complex concentrate.

Learning Objectives

Upon successful completion of this application-based course, participants should be able to:
1. Compare and contrast mechanisms of action, dosing, and side effects for andexanet alfa and prothrombin complex concentrate.
2. Discuss the concept of propensity score-overlap weighting.
3. Discuss the difference in patient outcomes after intracranial hemorrhage when given andexanet alfa versus prothrombin complex concentrates.
4. Analyze limitations for the use of andexanet alfa and prothrombin complex concentrates for factor Xa inhibitor reversal.
5. Apply clinical implications of the trial to a patient with apixaban- or rivaroxaban-associated intracranial hemorrhage.

Article Information

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read the article cited below.

Costa OS, Connolly SJ, Sharma M, et al. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixabanor rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Critical Care. 2022;26:180. https://doi.org/10.1186/s13054-022-04043-8

Faculty

Alicia Sacco, PharmD, BCCCP

Critical Care Clinical Pharmacy Specialist
Mayo Clinic Arizona

Disclosures:

Alicia Sacco has no relevant financial relationships with ineligible companies to disclose.

Course Details